Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis. - Suppr | 超能文献

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis.

作者信息

Olsen Catherine M, Green Adele C

机构信息

Cancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia.

Cancer and Population Studies Group, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4029, Australia.

出版信息

Ann Rheum Dis. 2018 Aug;77(8):e49. doi: 10.1136/annrheumdis-2017-212205. Epub 2017 Aug 22.

DOI:10.1136/annrheumdis-2017-212205

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: an updated meta-analysis.

Ann Rheum Dis. 2018 Aug;77(8):e49. doi: 10.1136/annrheumdis-2017-212205. Epub 2017 Aug 22.

2

Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.使用生物制剂治疗的类风湿关节炎患者发生侵袭性黑色素瘤的风险：来自11个欧洲生物制剂登记处合作项目的结果

Ann Rheum Dis. 2017 Feb;76(2):386-391. doi: 10.1136/annrheumdis-2016-209285. Epub 2016 Jun 15.

3

Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden.类风湿关节炎、抗肿瘤坏死因子治疗与鳞状细胞癌和基底细胞皮肤癌风险：基于瑞典全国前瞻性记录数据的队列研究

BMJ. 2016 Jan 28;352:i262. doi: 10.1136/bmj.i262.

4

Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis.使用肿瘤坏死因子α抑制剂治疗的类风湿关节炎患者的黑色素瘤风险：一项系统评价和荟萃分析。

Melanoma Res. 2016 Oct;26(5):517-23. doi: 10.1097/CMR.0000000000000284.

5

Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者：一项系统评价和网状Meta分析

Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.

6

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.类风湿关节炎、肿瘤坏死因子拮抗剂治疗与恶性黑色素瘤风险：来自瑞典的全国基于人群的前瞻性队列研究。

BMJ. 2013 Apr 8;346:f1939. doi: 10.1136/bmj.f1939.

7

[The proposal of the Croatian Society for Rheumatology for the treatment of adult rheumatoid arthritis patients with biologics, 2013].[克罗地亚风湿病学会关于使用生物制剂治疗成年类风湿关节炎患者的建议，2013年]

Reumatizam. 2013;60(1):47-51.

8

Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis.类风湿关节炎中生物制剂的减量：系统评价和荟萃分析。

Rheumatol Int. 2020 Dec;40(12):1949-1959. doi: 10.1007/s00296-020-04651-z. Epub 2020 Jul 24.

9

Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.联合使用传统改善病情抗风湿药物或生物制剂治疗的类风湿关节炎患者的炎症细胞因子水平、疾病活动度及功能

Clin Rheumatol. 2016 Jul;35(7):1673-81. doi: 10.1007/s10067-016-3306-x. Epub 2016 May 17.

10

Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析

Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.

引用本文的文献

1

Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis.生物治疗常见炎症性疾病患者的黑色素瘤风险：系统评价和荟萃分析。

JAMA Dermatol. 2020 Jul 1;156(7):787-794. doi: 10.1001/jamadermatol.2020.1300.

2

A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy.常规合成、生物制剂和靶向合成疾病修饰抗风湿药物治疗有恶性肿瘤病史的炎症性关节炎患者的实用方法。

Curr Rheumatol Rep. 2018 Sep 1;20(10):64. doi: 10.1007/s11926-018-0774-9.